Teva Pharmaceutical Industries Ltd. (TEVA)
40.39
+0.44
(+1.10%)
USD |
NYSE |
Oct 27, 16:00
39.69
-0.70
(-1.73%)
Pre-Market: 06:21
Teva Pharmaceutical Industries Enterprise Value : 60.28B for Oct. 27, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 27, 2026 | 60.28B |
| October 26, 2026 | 59.76B |
| October 23, 2026 | 59.14B |
| October 22, 2026 | 60.07B |
| October 21, 2026 | 60.55B |
| October 20, 2026 | 60.81B |
| October 19, 2026 | 61.35B |
| October 16, 2026 | 61.57B |
| October 15, 2026 | 61.12B |
| October 14, 2026 | 60.66B |
| October 13, 2026 | 61.28B |
| October 12, 2026 | 61.19B |
| October 09, 2026 | 61.10B |
| October 08, 2026 | 58.95B |
| October 07, 2026 | 58.87B |
| October 06, 2026 | 58.81B |
| October 05, 2026 | 59.43B |
| October 02, 2026 | 59.28B |
| October 01, 2026 | 59.02B |
| September 30, 2026 | 59.36B |
| September 29, 2026 | 59.60B |
| September 28, 2026 | 58.52B |
| September 25, 2026 | 58.88B |
| September 24, 2026 | 60.08B |
| September 23, 2026 | 58.67B |
| Date | Value |
|---|---|
| September 22, 2026 | 59.26B |
| September 21, 2026 | 59.89B |
| September 18, 2026 | 58.63B |
| September 17, 2026 | 58.88B |
| September 16, 2026 | 58.11B |
| September 15, 2026 | 58.95B |
| September 14, 2026 | 58.33B |
| September 11, 2026 | 56.33B |
| September 10, 2026 | 55.57B |
| September 09, 2026 | 56.15B |
| September 08, 2026 | 56.05B |
| September 04, 2026 | 55.58B |
| September 03, 2026 | 55.89B |
| September 02, 2026 | 56.90B |
| September 01, 2026 | 55.38B |
| August 31, 2026 | 55.22B |
| August 28, 2026 | 55.68B |
| August 27, 2026 | 57.05B |
| August 26, 2026 | 57.40B |
| August 25, 2026 | 57.61B |
| August 24, 2026 | 56.25B |
| August 21, 2026 | 56.72B |
| August 20, 2026 | 56.11B |
| August 19, 2026 | 56.88B |
| August 18, 2026 | 55.84B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Bristol Myers Squibb Co. | 159.73B |
| Merck & Co., Inc. | 396.88B |
| RedHill Biopharma Ltd. | -11.14M |
| AstraZeneca PLC | 553.83B |
| Eli Lilly & Co. | 1.253T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -585.89M |
| Revenue (Quarterly) | 4.221B |
| Total Expenses (Quarterly) | 4.807B |
| EPS Diluted (Quarterly) | -0.5029 |
| Gross Profit Margin (Quarterly) | 52.07% |
| Profit Margin (Quarterly) | -13.88% |
| Earnings Yield | 1.47% |
| Operating Earnings Yield | 6.94% |
| Normalized Earnings Yield | 3.930 |